NanoViricides Inc Total Liabilities
NanoViricides Inc total liabilities. Based on the latest financial reports, NanoViricides Inc (NNVC) has total liabilities worth $1.18 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NanoViricides Inc (NNVC) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of NanoViricides Inc (2005–2025)
Total liabilities of NanoViricides Inc from 2005 to 2025. This chart illustrates how NanoViricides Inc's total liabilities have evolved over time, based on quarterly financial data.
NanoViricides Inc Competitors by Total Liabilities
The table below lists competitors of NanoViricides Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Borneo Oil Bhd
KLSE:7036
|
Malaysia | RM121.47 Million |
|
Trek Metals Ltd
AU:TKM
|
Australia | AU$488.17K |
|
Environmental Clean Technologies Ltd
AU:ECT
|
Australia | AU$1.46 Million |
|
Tah Tong Textile Co Ltd
TW:1441
|
Taiwan | NT$933.58 Million |
|
NamSys Inc
V:CTZ
|
Canada | CA$1.55 Million |
|
MiniLuxe Holding Corp
V:MNLX
|
Canada | CA$17.25 Million |
|
Japan Gold Corp
V:JG
|
Canada | CA$412.89K |
Liability Composition Analysis (2005–2025)
This chart breaks down NanoViricides Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NNVC total asset value.
Liquidity & Leverage Metrics
NanoViricides Inc Total Liabilities Ratios Explained
NanoViricides Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NanoViricides Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NanoViricides Inc (2005–2025)
The table below shows the annual total liabilities of NanoViricides Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $1.31 Million | -3.85% |
| 2024-06-30 | $1.36 Million | -33.21% |
| 2023-06-30 | $2.03 Million | +392.75% |
| 2022-06-30 | $412.84K | +17.57% |
| 2021-06-30 | $351.15K | -83.72% |
| 2020-06-30 | $2.16 Million | -24.29% |
| 2019-06-30 | $2.85 Million | +222.94% |
| 2018-06-30 | $881.95K | -86.80% |
| 2017-06-30 | $6.68 Million | -50.82% |
| 2016-06-30 | $13.59 Million | +9.55% |
| 2015-06-30 | $12.40 Million | -22.32% |
| 2014-06-30 | $15.96 Million | +90.10% |
| 2013-06-30 | $8.40 Million | +371.89% |
| 2012-06-30 | $1.78 Million | +203.08% |
| 2011-06-30 | $587.18K | -76.26% |
| 2010-06-30 | $2.47 Million | +379.65% |
| 2009-06-30 | $515.72K | -49.66% |
| 2008-06-30 | $1.02 Million | +20.55% |
| 2007-06-30 | $849.88K | -43.00% |
| 2006-06-30 | $1.49 Million | +2159.13% |
| 2005-06-30 | $66.00K | -- |
About NanoViricides Inc
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product for… Read more